Who we serve
Legacy DNA partners with senior leaders whose decisions directly shape valuation, exit outcomes, and risk. While roles carry different pressures, they all influence the same equation:
Enterprise value isn’t created by products alone. It’s created by how clearly the market understands your value, how confidently buyers believe it, and how consistently growth holds up under scrutiny.
We help healthtech and pharmacy leaders prepare, strengthen, and elevate their companies for successful acquisition. And we do it through proven commercialization frameworks, valuation-driven storytelling, and focused GTM alignment.
You built something real.
Now it has to be understood, believed, and valued.
You’re leading a complex healthcare business with real customers, recurring revenue, regulatory gravity, and measurable impact. The fundamentals are strong. But valuation pressure is rising, diligence is inevitable, and the margin for error is shrinking.
You already see this dynamic with customers: when they don’t clearly understand your value, sales slow. Buyers behave the same way. If they miss what makes your business durable, defensible, or scalable, momentum — and money — are lost.
At the same time, you’re carrying the weight of aligning:
All while still running the business.
Legacy DNA helps CEOs and founders close the gap between what they know they’ve built and what the market actually sees. We focus on clarity, speed, and impact so your story holds up in customer conversations, boardrooms, and diligence alike.
You’re accountable for growth.
And for proving it matters.
You’re expected to operate marketing and sales as a growth engine. Campaigns run. Pipelines move. Revenue grows. Yet when the board asks how your work translates into enterprise value, the connection isn’t always clear.
Let's have a candid conversation to determine whether partnership makes sense. And what would actually move the needle.
The pressure is real to:
Legacy DNA partners with growth leaders who want to operate as strategic value creators. We help translate growth into clear narratives, credible proof, and metrics that boards and buyers believe.
Your work becomes easier to defend, easier to scale, and easier to tie directly to valuation outcomes.
Portfolio value depends on clarity, repeatability, and reduced risk.
Across portfolios, commercialization maturity is rarely consistent. Strong healthcare companies often underperform at exit because the valuation story doesn’t land cleanly, proof is uneven, or growth feels harder to replicate than expected.
Get a clear, senior-level view of where valuation risk and opportunity actually sit across the business.
We frequently see:
Legacy DNA works with operating and managing partners who need a repeatable value-creation system. We help establish shared commercialization frameworks, investor-ready narratives, and consistent revenue proof across healthtech and pharmacy portfolios.
Our role is to reduce risk, increase valuation confidence, and act as a practical bridge between operators, CEOs, and boards. Exit timelines stay clean and surprises don’t surface late.
